Structural Headwinds Outpace Pipeline Hope
PAT collapsed 61% YoY due to structural Lenalidomide and Semglutide headwinds. Management's raised FY27 PAT guidance to ~₹800 Cr is hedged with 'probably,' and H1's ₹409 Cr leaves no room for H2 disappointment.
₹202.6 Cr
-60.9% YoY
₹967.3 Cr
-29.0% YoY
19.9%
compression vs prior
~₹800 Cr
raised from 700-750 Cr, but hedged 'probably'
NATCO's 61% PAT decline to ₹202.6 Cr reflects not cyclical softness but structural earnings pressure. Lenalidomide revenue has cratered as 5-6 generic competitors flooded the market post-180-day exclusivity, with NATCO losing ₹200+ Cr YoY. Semglutide pricing has 'been really bad,' management said on the call; NATCO holds 5-6% volume and 3% value share in India's GLP-1 market, and profitability is 'long run, maybe.' Together, these two headwinds dwarf the ₹121 Cr Brazil business that grew 66% YoY and the emerging specialty oncology pipeline. The quarter is a reconciliation: reported profit collapsed despite revenue down only 29%. That gap—from -29% revenue to -61% PAT—is margin compression made plain.
Guidance raised—but it's really a hedge
On the surface, management upgraded FY27 PAT guidance to 'probably less than ₹800 Cr' from the prior 700-750 Cr range. That looks like a ~₹50-100 Cr raise at the midpoint. It is not. H1 actual PAT is ₹409 Cr (Q1 ₹206.5 Cr + Q2 ₹202.6 Cr), which is already 51% of the new ₹800 Cr target with just two quarters done. For FY27 to hit ₹800 Cr, H2 must deliver ₹391 Cr—essentially flat to H1 on an aggregate basis. Any H2 quarter below ₹195 Cr (the per-quarter average needed) misses the target. This leaves no buffer for further degradation, and management's hedging language ('probably') signals discomfort with committing.
More tellingly: prior FY27 revenue guidance was ₹3,400-3,500 Cr. Management has now withdrawn that target, saying they will offer 'clarity closer to year-end.' Q1 annualized implied ₹2,940 Cr. If FY27 comes in at ₹2,900-3,000 Cr, that is a ~15% revenue miss versus the prior guidance. The withdrawal signals downside revision is coming.
International formulation strong driver of QoQ growth
QoQ revenue +31.6%, YoY -29%. International growth offset by Lenalidomide collapse.
Overstated
Brazil business 66% growth highly encouraging
₹121 Cr confirmed at 66% YoY growth; but only ~12.5% of Q2 revenue from a small base.
Supported (contextualized)
Domestic improved with 20% bump, sustainable
₹145 Cr reported; core base ₹10-15 Cr. Semglutide stocking ₹130-135 Cr flagged as one-time.
Partial (overstated)
EBITDA margin 30.4% sustainable
EBITDA 30.4% confirmed, but NPM 19.9% shows weak PAT conversion. Semglutide unprofitable drag.
Overstated
FY27 PAT guidance on track
Guidance 'raised' to ~₹800 Cr but hedged 'probably.' H1 ₹409 Cr leaves tight H2 buffer.
Dodged (hedged)
What changed on this call
FY27 PAT guidance 'raised' to ~₹800 Cr (from 700-750 Cr) but heavily hedged with 'probably'
FY27 revenue guidance withdrawn; prior was ₹3,400-3,500 Cr. Downside revision signaled.
Semglutide profitability pushed to 'long run, maybe'—no near-term margin recovery path disclosed
CHS demerger delayed 4-6 months (now mid-year 2027) due to capital structure recertification
Adcock Ingram stake raised to 49% (from 36%); integration ongoing with seasonal earnings
The street lens: a 50% drawdown with selective repositioning
The stock is at ₹820.6, down 49.93% from its all-time high of ₹1,639. This is not quiet capitulation—volume is increasing and the RSI sits at 59.1 (neutral, not oversold)—but active repricing. The stock is trading above its 20-day (₹799.8) and 50-day (₹808.46) moving averages but well below its 200-day (₹926.17), confirming a medium-term downtrend overlaid on short-term bounce. For institutional investors, the picture is divergent: FII ownership has declined to 15.36% (Q3 FY27) from 16.00% in Q2 and 17.37% in Q4 FY26—a steady trim as foreign money exits. Meanwhile, domestic institutions have added modestly (DII up to 10.82% from 6.16% Q2). Promoters have trimmed slightly to 46.22% from 49.39%, likely dilution from the rights issue. The market repricing reflects the fundamental deterioration: earnings miss, margin compression, guidance hedging, and structural headwinds that management has only recently fully disclosed.
Bull-bear ledger
Carfilzomib (60 mg) FTF launch Q3 FY27; exclusivity expected to ramp in specialty oncology
Brazil business ₹121 Cr with 66% growth; expected 15-20% sustainable growth next year
Trabectedin and Olaparib launches in Q4 FY27; multiple specialty oncology products pending regulatory approval
CHS demerger mid-2027 expected to unlock standalone NATCO valuation
Lenalidomide revenue crater (₹200+ Cr YoY); 5-6 competitors, steep price erosion ongoing
Semglutide unprofitable drag; 5-6% volume, 3% value; no profitability near-term despite ₹130-135 Cr run-rate
FY27 PAT guidance hedged 'probably less than ₹800 Cr'; H1 ₹409 Cr leaves no H2 buffer for disappointment
Adcock integration complexity high; seasonal earnings (Q1 flu peak non-repeatable); regulatory approvals 2-3 years
Acquisition strategy vague; ₹2,250 Cr net cash but no target disclosed, PE multiples, or timeline
Risks ranked: what should concern a holder
Lenalidomide revenue crater continues
HIGH₹200+ Cr YoY loss from 5-6 generic competitors post-exclusivity. Shared first-to-file with steep price erosion ongoing. No recovery path disclosed.
Semglutide unprofitability persists
HIGH₹130-135 Cr quarterly run-rate contributing ₹0 margin. Management admits 'long run, maybe' on profitability. Earnings drag structural, not cyclical.
CHS demerger execution slips further
HIGHAlready delayed 4-6 months (now mid-2027). Expected ₹20 Cr EBITDA loss pre-demerger drags consolidated PAT. Regulatory (SEBI/NCLT) timeline uncertain.
H2 earnings disappointment
HIGHFY27 PAT target ~₹800 Cr requires H2 ₹391 Cr (essentially flat to H1). Single ₹10-15 Cr miss triggers guidance miss.
Adcock integration stalls or underperforms
MEDIUM49% stake, seasonal earnings (Q1 flu peak). One-time layoff charges in Q2. Regulatory approvals for South Africa portfolio 2-3 years out.
The debate
1 · Carfilzomib launch execution (Q3 FY27 expected)
First-to-file (60 mg) exclusivity should ramp volumes. Watch for physician adoption rates, pricing power, and gross margin. If launch is delayed or disappoints, the H2 PAT target becomes unachievable.
2 · H2 FY27 earnings trajectory
FY27 PAT target ~₹800 Cr requires H2 ≥₹391 Cr aggregate (flat to H1). Any Q3 or Q4 below ₹195 Cr signals further downgrade. Watch for Lenalidomide stabilization, Semglutide stocking tail, and acquisition contribution.
3 · Semglutide profitability path
Management admitted 'no profits in near future, maybe long run.' If Semglutide pricing stabilizes or volumes ramp without margin recovery by FY28, it becomes a permanent earnings drag. Watch pricing trends and competitive intensity.
4 · CHS demerger approval and timeline
Delayed from year-end FY27 to mid-2027. Any further slip extends pre-spin EBITDA losses (~₹20 Cr FY27 expected). Watch for SEBI/NCLT filings and regulatory commentary.
NATCO's Q2 is not the start of a recovery but the culmination of structural headwinds that have been building through FY27. Lenalidomide erosion and Semglutide unprofitability are not cyclical—they are structural margin drains. The specialty pipeline (Carfilzomib, Trabectedin, Olaparib) and Brazil momentum offer mid-term upside, but H1 earnings of ₹409 Cr on an ₹800 Cr FY27 target leave no room for further slippage. Management's hedged guidance language and withdrawn revenue guidance signal internal discomfort.
The stock is down 50% from its all-time high for a reason. Foreign institutions are trimming (FII down to 15.36%), and domestic buying has been modest. This is not capitulation pricing—it reflects a rational repricing of near-term earnings trajectory and execution risk.
What matters next: Can Carfilzomib launch stabilize margins in H2? Can H2 PAT reach ₹391 Cr? Can Brazil and ROW growth offset India headwinds? Until those questions are answered—not in forward guidance, but in actual H2 execution—expect the stock to trade defensively. The number to track from here is organic H2 PAT, not guidance hedges.
Informational and educational content only. Not investment advice.